Central team praises NTR district's efforts
On Wednesday, the Central government's TB Division team visited Vijayawada to assess the on-ground implementation of the 'TB Mukt Bharat Abhiyan' (TB-Free India Campaign) in the district. Their visit included a stop at the APIIC Colony Urban Primary Health Centre, where they reviewed the progress of the TB Mukt Bharat Abhiyan programme. They inquired about public awareness campaigns, disease diagnosis, distribution of free medicines to patients, and details of preventative measures. Subsequently, the teaminspected the CDST-TB Lab at Siddhartha Medical College, expressing satisfaction with the services provided.
District medical officials briefed the central team on the conduct of medical tests, provision of appropriate treatment, and details of nutritional support provided to patients through the Ni-kshay Poshan Yojana scheme. They also shared information regarding the distribution of nutritional kits by Ni-kshay Mitras (supporters). Officials explained that they are taking measures to identify TB patients in every village and provide them with improved treatment.
As part of their visit, the Central team interacted with Ni-kshay Mitras. Food kits were distributed to patients receiving treatment, with support from Vasavya Mahila Mandali and Apollo Tyres Healthcare Centre. The team also engaged with TB champions and felicitated them with medals.
Central team members Dr Bhawani Singh Kushwaha, Dr D Dharmarao, and Gangadhar Das, alongside State TB Officer Dr T Ramesh and District Medical and Health Officer Dr M Suhasini, Secretary of Vasavya Mahila Mandali G Rashmi and others participated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
a day ago
- NDTV
Higher Dose of This Antibiotic Can Help In Tuberculosis Recovery: Study
New Delhi: A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR). TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure. Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB. The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer. "Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance," said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai. Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB. "The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community," the researchers said. Notably, the study showed 20-30mg/kg rifampicin as the best balance. "This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment," revealed the study, published in the Indian Journal of Medical Research (IJMR). On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation. The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin. "High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment," the team said. "This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence," they added.
Hans India
a day ago
- Hans India
Lung TB: Higher dose of rifampicin safe, can boost recurrence-free survival, says ICMR study
New Delhi: A higher dose of rifampicin -- a bactericidal antibiotic used primarily to treat tuberculosis (TB) -- may be safe, and its use can potentially lead to recurrence-free survival in patients with pulmonary TB, according to a recent study by the Indian Council of Medical Research (ICMR). TB is curable but still remains the most common cause of death due to infectious diseases, with an estimated 1.3 million deaths globally in 2022. Rifamycins are a crucial drug group in the anti-TB regimen, which sterilise the lesions and aid in recurrence-free cure. Currently, rifampicin is administered at 10 mg/kg for six months to all patients with pulmonary TB. The team reviewed the available evidence from published clinical trials to determine whether higher doses of rifampicin (more than 15 mg/kg) are more efficacious and safer. 'Compared to standard dose, higher doses of rifampicin were found to lead to early sputum conversion in eight weeks and thus faster TB bacteria clearance,' said corresponding author Dr Leeberk Raja Inbaraj, Department of Clinical Research, ICMR- National Institute for Research in Tuberculosis, Chennai. Early sputum conversion is a valuable tool widely used as a surrogate marker for treatment response and those who are at risk for relapse in pulmonary TB. 'The ability of high-dose rifampicin to achieve early sputum conversion and eliminate the persistent bacteria that cause relapse could potentially lead to recurrence-free survival. Early bacterial clearance is also of public health importance as this could potentially reduce disease transmission in the community,' the researchers said. Notably, the study showed 20-30mg/kg rifampicin as the best balance. 'This dose range showed better sputum conversion without a significant increase in serious side effects and may be considered in TB treatment,' revealed the study, published in the Indian Journal of Medical Research (IJMR). On the other hand, doses above 30 mg/kg, although beneficial, came with severe side effects such as serious liver damage (hepatotoxicity) and adverse drug reactions (ADR), leading to treatment discontinuation. The study showed no reduction in death or treatment failure in people with more than 15 mg/kg doses of rifampicin. 'High doses did not reduce mortality or treatment failure at 6 months compared to standard treatment,' the team said. 'This dose could be administered with close monitoring of adverse events and hepatotoxicity. There is an urgent need for adequately powered trials that assess long-term treatment outcomes, including recurrence,' they added.
India.com
a day ago
- India.com
ICMR Trials Show Drones Can Deliver Blood In 15 Minutes, But Regulatory And Infrastructure Hurdles Remain
In a groundbreaking advancement for emergency healthcare, India has successfully tested drone technology to deliver blood, potentially revolutionizing medical logistics in the country. A 2023 trial by the Indian Council of Medical Research (ICMR) demonstrated that drones are capable of delivering blood over distances of 35 kilometers in just 15 minutes, a task that could have taken hours in Delhi's traffic-clogged roads. While the technology shows tremendous potential, experts warn that significant regulatory, logistical, and infrastructure hurdles must be overcome before such drone deliveries can be implemented nationwide. According to the ICMR report released in June, these trials demonstrated how drone-based delivery could significantly reduce time in critical situations, such as trauma care, surgeries, and maternal emergencies. The trial marked a major milestone in India's push for tech-driven healthcare solutions. Health experts and government officials have welcomed the development, calling it a potential 'game-changer.' However, the report also highlighted key challenges that must be addressed before widespread implementation. These include strict regulatory clearances from the Directorate General of Civil Aviation (DGCA), cold-chain maintenance during flight, trained drone operators, and secure take-off and landing zones, especially in congested urban areas. Through this advancement, India joined nations like Rwanda and Ghana, which have successfully used drones for medical deliveries in remote areas. The focus now shifts to integrating scientific advancements with streamlined regulations and robust infrastructure to scale up operations. With traffic congestion, delayed ambulance services, and uneven healthcare access still posing risks, drone delivery could be the life-saving solution that India needs but only if planning and implementation keep pace with innovation. Notably, in recent years, ICMR's i-Drone initiative has effectively used drones to transport critical medical supplies in regions such as Northeast India (including COVID-19 and UIP vaccines, medicines, and surgical equipment), Himachal Pradesh (to transport medicines and samples in high altitudes and freezing temperatures), Karnataka (for intraoperative oncosurgical samples), Telangana (for TB sputum samples), and NCR (for blood bags and their components). These initiatives demonstrate the growing potential and effectiveness of drones in bridging the last-mile healthcare gap. i-DRONE (ICMR's Drone Response and Outreach for North East) platform was originally conceived during the COVID-19 pandemic to deliver vaccines to remote regions.
